Clinical Trials List
2021-12-01 - 2025-06-30
Phase I/II
Recruiting5
ICD-10D47.4
Osteomyelofibrosis
ICD-10D68.51
Activated protein C resistance
ICD-10D68.52
Prothrombin gene mutation
ICD-10D68.59
Other primary thrombophilia
ICD-10D68.61
Antiphospholipid syndrome
ICD-10D68.62
Lupus anticoagulant syndrome
ICD-10D68.69
Other thrombophilia
ICD-10D75.81
Myelofibrosis
ICD-10D75.89
Other specified diseases of blood and blood-forming organs
ICD-10D77
Other disorders of blood and blood-forming organs in diseases classified elsewhere
ICD-10D89.2
Hypergammaglobulinemia, unspecified
ICD-10E88.09
Other disorders of plasma-protein metabolism, not elsewhere classified
ICD-9289.8
Other specified diseases of blood and blood-forming organs
-
Trial Applicant
PAREXEL INTERNATIONAL CO., LTD.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Jeng-Shiun Du 無
- Shih-Feng Cho 無
- Tsung-Jang Yeh 無
- Hui-Ching Wang 無
- 柯亞倫 無
- Yi-Chang Liu 無
- 高育青 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
20 participants
-
Global
57 participants
